| Aug 2 |
Agilent gets FDA approval for Tecelra companion diagnostic
|
| Aug 2 |
Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
|
| Aug 2 |
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
|
| Aug 2 |
Adaptimmune granted FDA accelerated nod for lead asset
|
| Aug 2 |
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
|
| Aug 2 |
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
|
| Jul 25 |
Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
|
| Jul 3 |
3 Biotech Moonshots With Imminent Catalyst Potential
|
| Jul 3 |
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
|
| Jul 3 |
5 FDA decisions to watch in the third quarter
|
